Motif Bio’s (MTFB) “Buy” Rating Reaffirmed at Peel Hunt
Other equities analysts also recently issued reports about the company. FinnCap reiterated a buy rating and set a GBX 100 ($1.34) target price on shares of Motif Bio in a research report on Thursday, August 24th. Northland Securities reiterated a buy rating on shares of Motif Bio in a research report on Monday, September 18th. Finally, Beaufort Securities reiterated a speculative buy rating and set a GBX 110 ($1.47) target price on shares of Motif Bio in a research report on Monday, October 2nd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Motif Bio has a consensus rating of Buy and an average price target of GBX 101.50 ($1.36).
Motif Bio (MTFB) opened at GBX 36 ($0.48) on Friday. The stock has a market capitalization of $94.79 and a price-to-earnings ratio of -133.33. Motif Bio has a 52 week low of GBX 22.50 ($0.30) and a 52 week high of GBX 51.75 ($0.69).
ILLEGAL ACTIVITY WARNING: “Motif Bio’s (MTFB) “Buy” Rating Reaffirmed at Peel Hunt” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/motif-bios-mtfb-buy-rating-reaffirmed-at-peel-hunt/1782960.html.
Motif Bio Company Profile
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with Analyst Ratings Network's FREE daily email newsletter.